- |||||||||| dilmapimod (SB-681323) / GSK, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer, talmapimod (SCIO-469) / J&J
Journal, Immunomodulating: Bioinformatic approach for repurposing immunomodulatory drugs for lepromatous leprosy. (Pubmed Central) - Dec 27, 2023
Consistently, glucosamine, binimetinib, talmapimod, dilmapimod, andrographolide, and VX-702 might have a possible beneficial effect coupled with LL treatment. Based on our drug repurposing analysis, immunomodulatory drugs might have a promising potential to be explored further as therapeutic options or to alleviate symptoms in LL patients.
- |||||||||| dilmapimod (SB-681323) / GSK
Trial completion: SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS (clinicaltrials.gov) - Apr 10, 2013
P2, N=90, Completed,
Based on our drug repurposing analysis, immunomodulatory drugs might have a promising potential to be explored further as therapeutic options or to alleviate symptoms in LL patients. Recruiting --> Completed
|
